Atreca, Inc. (BCEL)

NASDAQ: BCEL · IEX Real-Time Price · USD
2.02 0.01 (0.50%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap75.04M
Revenue (ttm)n/a
Net Income (ttm)-102.82M
Shares Out37.15M
EPS (ttm)-2.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume510,080
Open2.00
Previous Close2.01
Day's Range1.93 - 2.07
52-Week Range1.93 - 20.29
Beta-0.09
AnalystsStrong Buy
Price Target20.00 (+890.1%)
Earnings Daten/a

About BCEL

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. fo...

IndustryBiotechnology
IPO DateJun 20, 2019
CEOJohn Orwin
Employees137
Stock ExchangeNASDAQ
Ticker SymbolBCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Atreca stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 890.10% from the latest price.

Price Target
$20.00
(890.10% upside)
Analyst Consensus: Strong Buy

News

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

2 weeks ago - GlobeNewsWire

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

2 months ago - GlobeNewsWire

Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

2 months ago - GlobeNewsWire

Atreca Ink Licensing Pact With Gates Research On Malaria Antibody

Atreca Inc (NASDAQ: BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501 to prevent malaria.  MAM01/ATRC-501 is a monoclonal an...

3 months ago - Benzinga

Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

3 months ago - GlobeNewsWire

Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis...

5 months ago - GlobeNewsWire

Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101

Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET

5 months ago - GlobeNewsWire

Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors

SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique disc...

6 months ago - GlobeNewsWire

Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique disco...

8 months ago - GlobeNewsWire

Atreca Announces Poster Presentation at the Virtual American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a ...

10 months ago - GlobeNewsWire

Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

10 months ago - GlobeNewsWire

Atreca to Participate at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

11 months ago - GlobeNewsWire

Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

1 year ago - GlobeNewsWire

Atreca Announces Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

1 year ago - GlobeNewsWire

What Makes Atreca, Inc. (BCEL) a New Buy Stock

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Atreca to Present at Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discov...

1 year ago - GlobeNewsWire

Atreca, Inc. (BCEL) Upgraded to Buy: Here's Why

Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

1 year ago - GlobeNewsWire

Atreca to Present at Two Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

1 year ago - GlobeNewsWire

Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-bas...

1 year ago - GlobeNewsWire

Atreca, Inc. Announces Proposed Underwritten Public Offering of Class A Common Stock

REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immu...

1 year ago - GlobeNewsWire

All You Need to Know About Atreca, Inc. (BCEL) Rating Upgrade to Buy

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecif...

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutic...

1 year ago - GlobeNewsWire

Atreca Announces Webinar to Present ATRC-101 Preclinical Data Update on Monday, June 15, 2020

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

1 year ago - GlobeNewsWire

Atreca Announces Appointment of Kristine M. Ball to its Board of Directors

SOUTH SAN FRANCISCO, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discover...

1 year ago - GlobeNewsWire